Shots:Coralie started by giving a brief introduction about Systemic Mastocytosis (SM), a rare disease. She told us that in Europe, approximately 40,000 people live with SM, with 80-90% living with Indolent SM and the rest with Advanced SMShe then gave an overview of the P-II PATHFINDER study evaluating avapritinib. The study's 2-year follow-up…
